2 terminated, 2 unknown, 1 recruiting. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 2, Unknown 2, Recruiting 1 |
| Phase 1 | 2 | Terminated 2 |
Follow Relapsed or Refractory Acute Myeloid Leukemia (AML): new trials by email Literature Review of Relapsed or Refractory Acute Myeloid Leukemia (AML) trials Research Report on Relapsed or Refractory Acute Myeloid Leukemia (AML)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BCL2i CLAG-M in R/R Acute Myeloid Leukemia Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen, Venetoclax - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 52 | 2024-11-26 | 2026-04-01 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia Mitoxantrone Hydrochloride Liposome - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Terminated | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 1 | 2022-06-14 | 2024-02-23 |
| A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) HYML-122; cytarabine - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Unknown | Tarapeutics Science Inc. | 18 | 2022-03-29 | 2025-04-10 |
| A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) HYML-122 - Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 2 | Unknown | Tarapeutics Science Inc. | 15 | 2021-09-29 | 2024-05-14 |
| An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) KRT-232, Cytarabine, Decitabine - Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN) | Phase 1 / Phase 2 | Terminated | Kartos Therapeutics, Inc. | 70 | 2019-09-25 | 2024-03-22 |
Leukemia, Myeloid, Acute (5) · Recurrence (5)
Disease Attributes (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Leukemia (5) · Leukemia, Myeloid (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5)
Cytarabine (3) · Cladribine (1) · Clinical Protocols (1) · Decitabine (1) · Granulocyte Colony-Stimulating Factor (1) · Mitoxantrone (1) · navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid (1) · venetoclax (1)
Tarapeutics Science Inc. (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Kartos Therapeutics, Inc. (1)
China (3) · United States (2) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Hungary (1) · Israel (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Depei Wu, MD. PhD (2) · David Sallman, MD (1)